Monthly Archives: December 2020
Phase 2 SUMMIT study was a multicohort basket trial to evaluate the safety and efficacy of neratinib in patients with activating EGFR exon 18 or ERBB2 mutation solid tumors.
In a phase II umbrella trial, the VIKTORY trial, 715 gastric cancer patients underwent genomic sequencing and enrolled in the genomic matched cohort. Among the 715 patients, 25 (3.5%) patients harbored MET amplification and received savolitinib, a selective MET inhibitor. Tumor tissue and plasma ctDNA samples from the first three patients were obtained before treatment, during therapy, and at the time of progression.
SWI/SNF chromatin remodeling complex and PRC2 histone methyltransferase play an important role in regulating gene expression in normal cells. EZH2 is the catalytic subunit of PRC2. In the previous study, EZH2 upregulation is associated with dysfunction of the SWI/SNF in cancer cells.